On average, Wall Street analysts predict that Editas Medicine's share price could reach $ by Aug 8, The average Editas Medicine stock price. Find out the current price target and stock forecast for Editas Medicine (EDIT). See the latest Editas Medicine Inc stock price (EDIT:XNAS), related news, valuation, dividends and more to help you make your investing decisions. The current price of EDIT is USD — it has increased by % in the past 24 hours. Watch Editas Medicine, Inc. stock price performance more closely on the. See Editas Medicine, Inc. (EDIT) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades Analysis · Options · Holders.
View today's Editas Medicine Inc stock price and latest EDIT news and analysis. Create real-time notifications to follow any changes in the live stock. They create an illusion of a faltering company, hoping to profit from fear and uncertainty. The high short interest in Editas isn't just a bet. Real time Editas Medicine (EDIT) stock price quote, stock graph, news & analysis Editas Medicine (NASDAQ: EDIT). $ (%). -$ Price as of. Stock Quote & Chart · Chart Type. Mountain Open-High-Low-Close Candlestick Candlestick Red/Green Close Line % Change Fill % Change Line · Vertical Scale. Linear. A high-level overview of Editas Medicine, Inc. (EDIT) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and. Editas Medicine Inc. ; Open. $ Previous Close$ ; YTD Change. %. 12 Month Change. % ; Day Range · 52 Wk Range - According to 11 analysts, the average rating for EDIT stock is "Buy." The month stock price forecast is $, which is an increase of % from the. Quote Overview ; Dividend: (%) ; Beta: ; Most Accurate Est: ; Current Qtr Est: ; Current Yr Est: EDIT, Editas Medicine - Stock quote performance, technical chart analysis, SmartSelect Ratings, Group Leaders and the latest company headlines. See Editas Medicine, Inc. (EDIT) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades. Find the latest analyst research, reports, and ratings for Editas Medicine, Inc. Common Stock (EDIT) at 3458am.site
View Editas Medicine, Inc. EDIT stock quote prices, financial information, real-time forecasts, and company news from CNN. Find the latest Editas Medicine, Inc. (EDIT) stock quote, history, news and other vital information to help you with your stock trading and investing. Average Recommendation, Overweight. Average Target Price, Number Of Ratings, FY Report Date, 12/ Last Quarter's Earnings, Average Price Target Based on 12 Wall Street analysts offering 12 month price targets for Editas Medicine in the last 3 months. The average price target is €. Key Stats · Market CapM · Shares OutM · 10 Day Average VolumeM · Dividend- · Dividend Yield- · Beta · YTD % Change EDIT's current price target is $ Learn why top analysts are making this stock forecast for Editas Medicine at MarketBeat. The 10 analysts with month price forecasts for Editas Medicine stock have an average target of , with a low estimate of and a high estimate of EDIT Stock Overview · Revenue is forecast to grow % per year · Currently unprofitable and not forecast to become profitable over the next 3 years. EDIT | Complete Editas Medicine Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.
EDIT, Editas Medicine - Stock quote performance, technical chart analysis, SmartSelect Ratings, Group Leaders and the latest company headlines. 17 minutes ago. Editas Medicine Market Cap. Editas Medicine has a market cap or net worth of $ million as of September 3, Its market cap has decreased by % in. Stock analysis for Editas Medicine Inc (EDIT:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile. According to analysts, EDIT price target is USD with a max estimate of USD and a min estimate of USD.
Crispr Therapeutics Next Gen conditioning - competition and prospects
The stock price has decreased by % in the last 52 weeks. The beta is , so EDIT's price volatility has been higher than the market average. Beta (1Y). Editas Medicine (NASDAQ:EDIT) Stock, Analyst Ratings, Price Targets, Forecasts. Editas Medicine Inc has a consensus price target of $ based on the ratings. Editas Medicine Inc. analyst ratings, historical stock prices, earnings estimates & actuals. EDIT updated stock price target summary. Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. Editas Medicine had revenue of $K in the quarter ending June 30, , a decrease of %. This brings the company's revenue in the last twelve months.